Publications by authors named "Jennifer Way"
Article Synopsis
- Aggressive prolactin-secreting pituitary adenomas resistant to traditional therapies like dopamine agonists and surgery are challenging to treat; everolimus, an mTOR inhibitor, shows promise as a potential new option.
- A case study showed that adding everolimus to cabergoline treatment resulted in reduced prolactin levels and tumor regression after five months, with stable tumor size for 12 months.
- Immunohistochemical analysis revealed activation of the mTOR pathway in these tumors, suggesting that everolimus could effectively target aggressive prolactin-secreting tumors that don’t respond to standard treatments.
An 84-year-old woman with metastatic squamous cell carcinoma of the nasopharynx and no history of diabetes was started on the antiprogrammed cell death ligand-1 (anti-PD-L1) antibody durvalumab. Four months later, she presented in diabetic ketoacidosis with glucose 488 mg/dL, anion gap 16, positive serum ketones and A9.1%.
View Article and Find Full Text PDF